Molecular diagnostics company, Biocartis, has appointed Herman Verrelst as its new Chief Executive Officer (CEO).
Herman is a seasoned executive and serial entrepreneur with an international commercial track-record in molecular diagnostics.
Herman currently holds the position of Vice President and General Manager of the Genomics and Clinical Applications Division of Agilent Technologies, a global life sciences, diagnostics and applied chemical markets company, with revenues of $4.2bn in 2016.
In this role, Herman has been instrumental in expanding Agilent's product portfolio through product innovations and the addition of new technologies.
These were primarily in the area of precision genomics for oncology, the gateway to precision medicine, which is an excellent background to assist Biocartis in accelerating its worldwide commercial expansion and test menu development.
Herman joined Agilent in May 2015 as General Manager of the Clinical Applications Division following Agilent's acquisition of Cartagenia, of which Herman was CEO and founder.
Cartagenia was a spin-off of Katholieke Universiteit Leuven (Belgium) and was focused on software solutions for clinical genetics and molecular oncology.
Prior to that, Herman was CEO of Medicim, which was acquired by the Swiss-based Nobel Biocare in 2007, as well as founder and CEO of DATA4s, which was acquired by Norkom Technologies in 2004.
Herman holds a Master's degree in Electrical Engineering (Katholieke Universiteit Leuven, Belgium).